There is a current ongoing trial (NCT02159495) where patients are being administered autologous anti-CD123 CAR-T cells for patients with CD123+ relapsed or refractory AML or CD123+ persistent or recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (69). The gene discussed is IL3RA; the disease is acute myeloid leukemia.